← Back to Clinical Trials
Recruiting NCT06732219

NCT06732219 A Single-Arm Pilot Trial for Mitigating Relapse of Severe Problem Behavior

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06732219
Status Recruiting
Phase
Sponsor Auburn University
Condition Challenging Behavior
Study Type INTERVENTIONAL
Enrollment 10 participants
Start Date 2024-11-14
Primary Completion 2026-08

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age 17 Years
Study Type INTERVENTIONAL
Interventions
Functional Communication TrainingExtinction-Correlated StimuliCaregiver Fading

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 10 participants in total. It began in 2024-11-14 with a primary completion date of 2026-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to improve how we teach self-control and communication skills to children and adolescents with challenging behaviors. Researchers aim to find ways to make behavior-change treatments more effective and long-lasting, even when the environment or reinforcement schedules change. The main questions this study will answer are: Can innovative techniques help children maintain learned skills, such as asking for attention or waiting for rewards, when faced with new people, places, or situations? How do cognitive and behavioral factors, like memory, timing, and decision-making, affect the success of treatments? Participants in this study will: Complete assessments to identify preferred activities and understand the causes of challenging behaviors. Learn communication skills to replace challenging behaviors, such as tantrums or crying, with more appropriate actions like asking for attention. Participate in activities designed to understand their individual responses to different types of rewards and delays.

Eligibility Criteria

We will include individuals between the ages of 6 to 17 with IDD who have at least one topography of SPB that is maintained by social positive (e.g., attention, access to preferred items) reinforcement. The age range is driven by the need to maximize the number of participants; there is no evidence to suggest that age is a relevant variable regarding relapse of SPB.

Contact & Investigator

Central Contact

John M Falligant, PhD

✉ jmf0031@auburn.edu

📞 334-844-4412

Principal Investigator

John Falligant, PhD

PRINCIPAL INVESTIGATOR

Auburn University

Frequently Asked Questions

Who can join the NCT06732219 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, up to 17 Years, studying Challenging Behavior. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06732219 currently recruiting?

Yes, NCT06732219 is actively recruiting participants. Contact the research team at jmf0031@auburn.edu for enrollment information.

Where is the NCT06732219 trial being conducted?

This trial is being conducted at Auburn, United States, Baltimore, United States.

Who is sponsoring the NCT06732219 clinical trial?

NCT06732219 is sponsored by Auburn University. The principal investigator is John Falligant, PhD at Auburn University. The trial plans to enroll 10 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology